Ascletis Pharma, Inc.

Sagimet Bioscience’s denifanstat has met all primary, key secondary and secondary endpoints in a Phase III clinical trial in China for the treatment of moderate-to-severe acne vulgaris conducted by gr

Ascletis Pharma only joined the obesity field last September but has just presented early data for what could be a best-in-class oral GLP-1 agonist. Data from the Phase Ib MAD study show the Hong Kong

Viking Therapeutics, Inc. now looks poised to win the first round in a string of legal actions it has taken against Chinese firm Ascletis Pharma, Inc. , in which the US biotech alleged infringement

Bristol Myers Squibb Company and Sanofi recently joined the ranks of companies cutting costs and jobs in 2024, although not necessarily for the same reasons, as first quarter earnings season got un